AD vaccines: conclusions and future directions.
Wisniewski
Thomas
T
New York University School of Medicine, Millhauser Laboratory, New York, NY 10016, USA. thomas.wisniewski@nyumc.org
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D023582:Alzheimer Vaccines / Q000276:immunology / Q000302:isolation & purification / Q000494:pharmacology*; D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism; D000818:Animals; D016657:Cerebral Amyloid Angiopathy / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D002986:Clinical Trials as Topic / Q000592:standards; D004195:Disease Models, Animal; D015195:Drug Design; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods* / Q000592:standards / Q000639:trends; D016874:Neurofibrillary Tangles / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D058225:Plaque, Amyloid / Q000187:drug effects* / Q000378:metabolism
D023582:Alzheimer Vaccines; D016229:Amyloid beta-Peptides